Amicus Sustainability Profile
Amicus Therapeutics, often referred to simply as Amicus, is a prominent biopharmaceutical company headquartered in the United States. Founded in 2002, Amicus has established itself as a leader in the development of innovative therapies for rare and orphan diseases, particularly in the field of enzyme replacement therapy. With a strong focus on advancing treatments for conditions such as Fabry disease and Pompe disease, Amicus is recognised for its unique approach to drug development, utilising cutting-edge technology and patient-centric strategies. The company has achieved significant milestones, including the successful launch of its flagship product, which has positioned it favourably within the competitive biopharmaceutical landscape. Amicus continues to expand its operational reach, with a commitment to improving the lives of patients worldwide through its specialised therapies and robust research initiatives.
DitchCarbon Score
How does Amicus's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Amicus's score of 26 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Amicus's reported carbon emissions
In 2020, Amicus Therapeutics, headquartered in the US, reported total carbon emissions of approximately 302,400 kg CO2e. This figure represents the company's overall emissions but does not specify the breakdown into Scope 1, 2, or 3 emissions, as no detailed scope data has been disclosed. Currently, Amicus has not established any formal reduction targets or commitments, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi). The absence of specific climate pledges or reduction initiatives indicates that the company may be in the early stages of developing a comprehensive climate strategy. As of now, there is no cascaded emissions data from a parent or related organization, meaning all reported figures are directly from Amicus Therapeutics, Inc. The company’s emissions data and climate commitments will be crucial for stakeholders looking to understand its environmental impact and future sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | |
|---|---|
| Scope 1 | - |
| Scope 2 | - |
| Scope 3 | - |
How Carbon Intensive is Amicus's Industry?
How Carbon Intensive is Amicus's Location?
Amicus's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Amicus has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.